Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm

Executive Summary

Roche's up and down ESMO is best summed up by the response to data presented on its personalised cancer med entrectinib – good but perhaps not as good as others.

Advertisement

Related Content

New Company, Big Goal: Serial Entrepreneur Jonathan Lim Launches Erasca To 'Erase Cancer'
Q3 Pharma Earnings Preview: AbbVie, Lilly, AstraZeneca And Bayer
Q3 Pharma Earnings Preview: Novo Nordisk, Shire And Teva
Roche Pushes Personalization With $2.4bn Foundation Buy-Out
Roche Ramps Up Cancer Portfolio With $1.7bn Ignyta Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124051

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel